FOLFIRI regimen in advanced colorectal cancer: The experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM)

Evaristo Maiello, V. Gebbia, F. Giuliani, G. Paoletti, N. Gebbia, N. Borsellino, G. Cartenì, G. Pezzella, L. Manzione, S. Romito, M. Lopez, G. Colucci

Research output: Contribution to journalArticlepeer-review


Purpose: To verify the experience of the GOIM in the treatment of advanced colorectal cancer patients with the FOLFIRI combination therapy. Patients and methods: Patients entered in three consecutive trials of the GOIM (protocols no. 9706, 9901, and 2301) were reported in this analysis. A total of 287 chemotherapy-naive patients were treated with FOLFIRI regimen: Irinotecan 180mg/m2 on day 1 with LV5FU2 regimen (LV at 100mg/m2 administered as a 2-hour infusion before FU at 400mg/m2 as an intravenous bolus injection, and FU at 600mg/m2 as a 22-hour infusion immediately after 5FU bolus injection on day 1 and 2); the treatment was repeated every 2 weeks. Results: 287 patients entered in these three trials, and 264 (92%) were evaluable for response. The overall response rate was 34.5% (95% confidence interval [CI]: 29% to 40%). When only assessable patients were analyzed, overall response rate was 37% (95% CI: 31% to 43%). Median time to progression, median duration of response and survival were 7 months, 10.5 months and 14 months, respectively. All but three patients were evaluable for toxicity which was globally mild; grade 3-4 toxicity was uncommon, and gastrointestinal disturbances were the most common. Conclusions: FOLFIRI regimen is effective and well-tolerated as first-line treatment in patients with advanced colorectal cancer. Further studies needed to evaluate the improvement in results with the addition of new drugs to this combination therapy.

Original languageEnglish
JournalAnnals of Oncology
Issue numberSUPPL. 4
Publication statusPublished - May 2005


  • Colorectal cancer
  • Combination therapy
  • Fluorouracil
  • Folinic acid
  • Irinotecan

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'FOLFIRI regimen in advanced colorectal cancer: The experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM)'. Together they form a unique fingerprint.

Cite this